ストックスクリーナーアプリを入手
258.81
5.90%
-16.83
アフターアワーズ：
258.81
Krystal Biotech Inc (KRYS) 最新ニュース
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed? - Sahm
Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Yahoo Finance
Krystal Biotech director Janney sells shares worth $10.1 million - Investing.com
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 700 Shares - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 37,895 Shares - MarketBeat
Daniel Janney Sells 7,741 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech Director Janney Daniel Sells Over $16 Million in Company Stock - TradingView
KRYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Cuts Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone - simplywall.st
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Krystal Biotech (NASDAQ:KRYS) Given New $284.00 Price Target at Guggenheim - MarketBeat
Guggenheim Raises Price Target for Krystal Biotech (KRYS) to $284 | KRYS Stock News - GuruFocus
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN
Risk On: Can Krystal Biotech Inc weather a recessionJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Insider Unloading: Dino A Rossi Sells Options, Realizes $5.04M - Benzinga
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Krystal Biotech’s KB707 RMAT Win Opens New Lung Cancer Chapter - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock - MarketBeat
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million - Investing.com
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million By Investing.com - Investing.com India
Director at Krystal Biotech (NASDAQ: KRYS) sells 18,950 shares - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: An Investor's Guide To A Promising 17% Upside - DirectorsTalk Interviews
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 - Yahoo Finance
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating - Finviz
Aug EndMonth: What is the long term forecast for Giftify Inc stockInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Analysts Offer Predictions for Krystal Biotech Q2 Earnings - MarketBeat
Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Trading Down 6.9%Here's Why - MarketBeat
HC Wainwright Forecasts Krystal Biotech Q1 Earnings - MarketBeat
Why Analysts See Krystal Biotech (KRYS) Story Shifting After New Data And Target Resets - Yahoo Finance
Krystal Biotech (KRYS): Citigroup Raises Price Target to $371 | - GuruFocus
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail
Reassessing Krystal Biotech (KRYS) After Strong 1-Year Rally And Vyjuvek Pipeline Focus - Yahoo Finance
Krystal Biotech stock reaches all-time high at 296.78 USD By Investing.com - Investing.com Australia
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark - Finviz
Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline - TipRanks
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $323.00 - MarketBeat
KRYS: Chardan Capital Raises Price Target to $323.00, Maintains Buy Rating | KRYS Stock News - GuruFocus
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts - Benzinga
Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook - MSN
MSN Money - MSN
Readystate Asset Management LP Sells 77,631 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
CSL licenses Eli Lilly's clazakizumab to cut cardiac risk in end-stage kidney disease - AOL.com
Krystal Biotech (NASDAQ:KRYS) Hits New 1-Year High After Earnings Beat - MarketBeat
Decoding Krystal Biotech Inc (KRYS): A Strategic SWOT Insight - GuruFocus
KRYS Krystal Biotech Feb 17, 2026 Jefferies Maintains Buy - Meyka
Krystal Biotech Earnings Call Highlights Profitable Growth - TipRanks
Krystal Biotech (KRYS) Reports Strong Q4 Revenue and Expansion P - GuruFocus
Krystal Biotech (KRYS) Q4 2025 Earnings Transcript - AOL.com
Krystal Biotech earnings beat by $0.12, revenue topped estimates - Investing.com Canada
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology (NASDAQ:KRYS) - Seeking Alpha
3.01%
2.69%
大文字化:
|
ボリューム (24 時間):